Ibandronate for postmenopausal osteoporosis: a Meta-analysis

doi:10.3969/j.issn.2095-4344.2016.20.017

Abstract

Abstract:

BACKGROUND: Alendronate has a marked enhancing effect on bone mineral density. Ibandronate is the newest (the third generation) bisphosphonates. Evidence-based medicine data on the therapeutic effects of both two drugs remain lacking because of different administration routes and time.
OBJECTIVE: To compare the therapeutic effects of ibandronate and alendronate on postmenopausal osteoporosis.
METHODS: A computer-based online search was conducted in CNKI, PubMed, CECDB, BMA, VIP, CQVIP, CBM, EMbase, ASP, The Cochrane Library, and EMCC databases from August 1999 to August 2015 to screen the relevant randomized controlled trials. Meta-analysis was performed using Stata/SE version 12.0 software by extracting data from the relevant articles.
RESULTS AND CONCLUSION: A total of 10 randomized controlled trials involving 725 patients (ibandronate and alendronate for 379 and 346 patients, respectively) were included. The meta-analysis results showed that bone mineral density was significantly increased (P=0.174, I2= 29.4%, WMD=0.03, 95%CI (0.01-0.04)) at 6 months after treatment and incidence rate of fracture was significantly decreased (P=5.810, I2=0%, OR=0.32, 95%CI: (0.10-1.00)) during 1-year treatment with ibandronate compared with alendronate treatment. However, no significant differences were found between two drug treatments in lumbar spine bone mineral density at 1 year after treatment and the incidence rate of fracture during 6-month treatment. Six-month treatment of ibandronate can improve bone mineral density and reduce the incidence rate of fracture of patients with postmenopausal osteoporosis.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Diphosphonates, Osteoporosis, Postmenopausal, Tissue Engineering

CLC Number:

R318

Liu Lei, Tao Sheng-xiang. Ibandronate for postmenopausal osteoporosis: a Meta-analysis[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(20): 3012-3021.

Figures/Tables 6

References

[1] Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.Curr Med Res Opin. 2008;24(1): 237-245.

[2] Hopkins RB, Goeree R, Pullenayegum E, et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women.BMC Musculoskelet Disord. 2011;26(12): 209-210.

[3] Wallace DJ.Rapid prevention of vertebral fractures associated with osteoporosis.Orthopedics. 2005;28(3): 291-298.

[4] 吕淑兰,邹余粮,曹缵孙,等.围绝经期妇女激素替代治疗的临床研究[J].西安医科大学学报. 2001,22(6): 552-554.

[5] Baim S, Wilson CR, Lewiecki EM, et al. Precision assessment and radiation safety for dual-energy x-ray absorptiometry:position paper of the International Society for Clinical Densitometry.J Clin Densitom. 2005;8(8): 371-378.

[6] 连帆,王于,杨岫岩,等.绝经后骨质疏松治疗方法的近期疗效观察与比较[J].中山大学学报:医学科学版,2011, 32(3): 379-382.

[7] Bachrach LK. Osteoporosis and measurement of bone mass in children and adolescents. Endocrinol Metab Clin North Am.2005;34(10):521-535.

[8] Ann C, Peter T, Jonathan A, et al. Mela-analysis of risedrormte for the treatment of postmenopausal women. Endocrine Reviews.2002;23(4):508-523.

[9] Bone HG, Hosking D, Devogelaer JP. Ten years experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med.2004; 350(6): 1189-1199.

[10] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 21(7):339-340.

[11] Leandro G. Meta-analysis in Medical Research. Massachusetts:Blackwell Publishing Ltd.2005:74-78.

[12] 中华医学会,骨科学分会.骨质疏松骨折诊疗指南[J].中华骨科杂志,2008,28(10):875-878.

[13] Kanjs JA, Burlet N, Cooper c, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Oneoporos Int.2008;19(7): 399-428.

[14] 周建烈,李乃青.美国NOF预防和治疗骨质疏松的最新临床指南简介[J].中国骨质疏松杂志,2009,15(6):471-472.

[15] 李静, 李幼平. 不断完善与发展的CochraneMeta分析[J].中国循证医学杂志,2008,8(9):742-743.

[16] Higgins JPT, Green S．Cochrane Handbook for Systematic Reviews of Interventions version 5.0.2.The Cochrane Collaboration. 2009:201-203.

[17] Turpin DL. CONSORT and QUOROM guidelines for reporting randomized clinical trials and systematic reviews. American journal of orthodontics and dentofacial orthopedics: official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics. 2005;128(6):681-685.

[18] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled clinical trials.1996; 17(1):1-12.

[19] Walsh C, Walsh S, Tang T, et al. Total abdominal hysterectomy versus total laparoscopic hysterectomy for benign disease: A meta-analysis. Eur J Obstet Gynecol Reprod Biol.2009;144(1):1-2.

[20] Liberati A, Altman D G, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.BMJ.2009; 21(6): 339-340.

[21] 王丹,翟俊霞,牟振云,等.Meta分析中的异质性及其处理方法[J].中国循证医学杂志,2009,9(10):1115-1118.

[22] Brian S E, Torsten H. A handbook of statistical analyses using R.CRC press.2006:163-169.

[23] 麦劲壮,李河,方积乾,等. Meta分析中失安全系数的估计[J].循证医学,2006,6(5):297-300.

[24] Dando TM, Noble S. Once-monthly ibandronate.Treat Endocrinol. 2005;4(6):381-387.

[25] Emkey R, Delmas PD, Bolognese M, et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.Clin Ther. 2009;31(4):751-761.

[26] Pyon EY. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.Clin Ther. 2006;28(4):475-490.

[27] Rizzoli R. Bisphosphonates for post-menopausal osteoporosis: are they all the same?.QJM. 2011; 104(4): 281-300.

[28] Sambrook P.Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.Clin Interv Aging. 2007;2(1):65-72.

[29] Sieber P, Lardelli P, Kraenzlin CA, et al. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.Clin Drug Investig. 2013;33(2): 117-122.

[30] Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.Clin Rheumatol. 2008; 27(8):955-960.

[31] Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis.Drug Saf. 2007;30(9):755-763.

[32] 包丽华,林华,李永军,等.伊班膦酸钠和阿仑膦酸钠对绝经后骨质疏松的干预研究[J].中国骨质疏松杂志.2011, 17(3): 232-235.

[33] 李改丽,呼永河,张汝,等.伊班膦酸钠输注液和阿伦膦酸纳片防治老年性骨质疏松症的疗效对比研究[J].中国全科医学,2012,15(30):3469-3472.

[34] Bonnick SL, Silverman S, Tanner SB, et al. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.J Womens Health (Larchmt). 2009; s18(7): 935-943.

[35] Schafer AL, Burghardt AJ, Sellmeyer DE, et al. Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).Osteoporos Int. 2013;4(16):53-54.

[36] Johnson N, Barlow D, Lethaby A, et al. Methods of hysterectomy: systematic review and meta-analysis of randomised controlled trials. BMJ.2005;330(7506): 1478-1480.